| scholarly article | Q13442814 |
| P50 | author | Olivier Thaunat | Q64918274 |
| Florent Guerville | Q83841085 | ||
| P2093 | author name string | Jean-Luc Taupin | |
| Emmanuel Morelon | |||
| Lionel Couzi | |||
| Peter Nickerson | |||
| Sébastien Lepreux | |||
| Pierre Merville | |||
| Valérie Dubois | |||
| Gwendaline Guidicelli | |||
| Jonathan Visentin | |||
| Chris Wiebe | |||
| Thomas Bachelet | |||
| P2860 | cites work | Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data | Q31004418 |
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Effect of antibodies on endothelium | Q35547335 | ||
| A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody | Q36887068 | ||
| Nonadherence consensus conference summary report. | Q37365665 | ||
| Complement: coming full circle. | Q37623518 | ||
| The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo | Q37819943 | ||
| The role of complement in antibody-mediated rejection in kidney transplantation | Q38048605 | ||
| Incidence and impact of de novo donor-specific alloantibody in primary renal allografts | Q39472834 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients | Q43856835 | ||
| HLA antibody specification using single-antigen beads--a technical solution for the prozone effect | Q43914521 | ||
| Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 | ||
| The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes | Q44174433 | ||
| Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. | Q44260404 | ||
| Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation | Q44418324 | ||
| Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes | Q44598524 | ||
| Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies | Q45332005 | ||
| Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Reduced exposure to calcineurin inhibitors in renal transplantation | Q46840533 | ||
| Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules | Q47272995 | ||
| Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 | ||
| Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. | Q50618048 | ||
| NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. | Q51676450 | ||
| Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. | Q52889823 | ||
| Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. | Q53032138 | ||
| Pretransplant Donor-Specific HLA Class-I and -II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure | Q60182181 | ||
| Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts | Q79576266 | ||
| Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction | Q80379527 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation | Q82659907 | ||
| Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation | Q82732578 | ||
| Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay | Q83063969 | ||
| Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes | Q83610924 | ||
| Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection | Q84261290 | ||
| Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients | Q85963365 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 615-625 | |
| P577 | publication date | 2015-06-05 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival | |
| P478 | volume | 27 |
| Q51682057 | Anti-Donor HLA Antibody Response After Pancreatic Islet Grafting: Characteristics, Risk Factors, and Impact on Graft Function. |
| Q36113914 | Antibody-Dependent NK Cell Activation Is Associated with Late Kidney Allograft Dysfunction and the Complement-Independent Alloreactive Potential of Donor-Specific Antibodies |
| Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
| Q36380010 | Application and interpretation of histocompatibility data in pediatric kidney transplantation. |
| Q87395286 | Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients |
| Q42722931 | Bad Memory: CD4 T Cell Presensitization Fosters Antibody-Mediated Kidney Transplant Rejection. |
| Q39384930 | Biomarkers to detect rejection after kidney transplantation. |
| Q40417954 | C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study |
| Q90450246 | Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection |
| Q52586350 | Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction. |
| Q59807564 | Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients |
| Q46970385 | Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment |
| Q54969814 | Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. |
| Q34047345 | Current status of alloimmunity |
| Q48955987 | De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis |
| Q40468571 | De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability. |
| Q47839666 | Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury |
| Q28075921 | Detection of HLA Antibodies in Organ Transplant Recipients - Triumphs and Challenges of the Solid Phase Bead Assay |
| Q26738469 | Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation |
| Q39265221 | Donor-Specific Antibodies in Kidney Transplant Recipients |
| Q48271656 | Donor-specific antibodies' C1q binding: improvement in kidney graft management? |
| Q37642331 | Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications. |
| Q51563025 | Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. |
| Q37590820 | From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. |
| Q64069939 | Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes |
| Q47795834 | Immunogenicity of Class I HLA but not preformed low MFI donor specific antibodies correlates with outcomes after first renal transplantation |
| Q92424284 | Increased circulating Tfh to Tfr ratio in chronic renal allograft dysfunction: a pilot study |
| Q89594061 | Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-γ+CD8+T cells with De Novo DSA Production in the First Year After Kidney Transplant |
| Q91451420 | Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants |
| Q38773711 | Moving Biomarkers toward Clinical Implementation in Kidney Transplantation |
| Q99578010 | Preemptive HLA Antibody Screening Prior to Episodic Transplant Renal Biopsy Enables Early Diagnosis and Therapeutic Response in Asymptomatic Chronically Active Antibody-Related Rejection: A Case Report |
| Q50000836 | Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board. |
| Q47157742 | Renal allograft rejection, lymphocyte infiltration, and de novo donor-specific antibodies in a novel model of non-adherence to immunosuppressive therapy |
| Q38558820 | Sensitization assessment before kidney transplantation |
| Q39340117 | Strategies for long-term preservation of kidney graft function |
| Q30397251 | The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies |
| Q51010023 | The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. |
| Q89148849 | Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients |
| Q40634986 | Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss |
| Q38818479 | mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now? |
Search more.